Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06495723Phase 1Recruiting

Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

Role: lead

NCT06154291Phase 1Recruiting

FIH XON7 in Advanced/Metastatic Solid Tumors

Role: lead

NCT04928430Phase 2Terminated

Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

Role: lead

NCT04431219Phase 1Completed

First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients

Role: lead

NCT05307406Phase 1Completed

A First-in-Human Study With XAB05 in Healthy Subjects

Role: lead

NCT04453384Phase 2Completed

Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia

Role: collaborator

All 6 trials loaded